Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Cyclopharm Limited ( (AU:CYC) ).
Cyclopharm Limited has disclosed a change in the interests of director David James Heaney, who holds his stake via Mount Melleray Pty Ltd as trustee for The Heaney Super Fund. The filing outlines his direct interest in ordinary shares of the company as required under Australian corporate and listing rules.
Heaney increased his holding by acquiring 21,052 ordinary shares on 12 March 2026 through participation in Cyclopharm’s Share Purchase Plan, taking his total interest from 310,000 to 331,052 shares. The transaction, valued at $19,999.40, signals director support for the company’s capital management initiatives while indicating there were no trades during a closed period and no changes to any related contracts.
The most recent analyst rating on (AU:CYC) stock is a Hold with a A$0.69 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an Australian healthcare company listed on the ASX that operates in the medical technology and pharmaceutical sector. The company is involved in the manufacture and supply of specialised medical products, with its securities traded as ordinary shares on the Australian market.
Average Trading Volume: 89,869
Technical Sentiment Signal: Sell
Current Market Cap: A$88.05M
Find detailed analytics on CYC stock on TipRanks’ Stock Analysis page.